Sign In
Buy NUVL
$90.18
-1.17 (-1.28%)
At Close: Jun 03, 2026
Nuvalent: Pivotal NSCLC Programs Progressing With Additional Data In 2024
02:55pm, Monday, 26'th Feb 2024
Nuvalent, Inc. expects final results from the phase 1 ARROS-1 study, using NVL-520 for the treatment of patients with ROS-1 positive non-small cell lung cancer, in 2024 at a medical meeting. Final res
Nuvalent Initiates the Phase 2 Portion of ALKOVE-1 Clinical Trial for Patients with ALK-Positive NSCLC and other Solid Tumors
06:30am, Monday, 12'th Feb 2024
Alignment with US Food and Drug Administration on a Recommended Phase 2 Dose for NVL-655 of 150 mg once daily Phase 2 Designed with Registrational Intent for TKI Pre-Treated Patients with ALK-Positive
Nuvalent to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
06:30am, Thursday, 01'st Feb 2024
CAMBRIDGE, Mass. , Feb. 1, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kin
Nuvalent Announces "OnTarget 2026" Operating Plan and Key Anticipated Milestones
06:30am, Monday, 08'th Jan 2024
Targeting first approved product in 2026 towards realizing mission of bringing new, potential best-in-class treatments to patients with cancer Well-capitalized to support OnTarget 2026 initiatives wit
Nuvalent to Present at the 42nd Annual J.P. Morgan Healthcare Conference
06:30am, Thursday, 21'st Dec 2023
CAMBRIDGE, Mass. , Dec. 21, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kina
Nuvalent Highlights Corporate and Pipeline Achievements and Reports Third Quarter 2023 Financial Results
06:30am, Tuesday, 14'th Nov 2023
Presented preliminary Phase 1 clinical data from ALKOVE-1 trial of NVL-655, initiated Phase 2 portion of ARROS-1 trial of NVL-520, and continued advancement of NVL-330 toward clinical development Appo
Nuvalent to Participate in the BMO Virtual BioPharma Spotlight Series: Oncology Day
06:30am, Wednesday, 01'st Nov 2023
CAMBRIDGE, Mass. , Nov. 1, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinas
7 Biotech Stocks to Get In Now Before Investors Catch On
02:50am, Monday, 23'rd Oct 2023
Biotechnology is the source of some of our strongest and growing revolutions. Gene technology allows us to cure incurable diseases and make miracles happen with living organisms.
Why Nuvalent Stock Tanked on Tuesday
06:27pm, Tuesday, 17'th Oct 2023
The biotech announced a secondary share flotation. It will sell over 5 million shares of its common stock in a public offering.
Nuvalent Announces Pricing of Public Offering of Common Stock
09:55pm, Monday, 16'th Oct 2023
CAMBRIDGE, Mass., Oct. 16, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinas
Nuvalent Announces Public Offering of Common Stock
07:30am, Monday, 16'th Oct 2023
CAMBRIDGE, Mass. , Oct. 16, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kina
Encouraging preliminary signs of activity observed in heavily pre-treated patients with ALK-positive NSCLC, including in subgroups of patients who have previously received a 2nd generation ALK TKI and
Why Nuvalent Stock Skyrocketed 35% This Week
07:13pm, Thursday, 05'th Oct 2023
Nuvalent announced favorable preliminary data from a phase 1 trial indicating its drug NVL-655 was well tolerated with mild adverse events. It's still early, but management is encouraged by the data.
Nuvalent (NUVL) Soars 36% on Upbeat Initial NSCLC Study Data
12:02pm, Thursday, 05'th Oct 2023
Nuvalent (NUVL) surges 36% on encouraging preliminary results from the phase I dose-escalation portion of its early-mid-stage development program for NVL-655 to treat advanced ALK-positive NSCLC.
Nuvalent Stock Gains On Lung Cancer Data, But I'd Only Buy On Dip
11:00am, Thursday, 05'th Oct 2023
Nuvalent, Inc. stock gained 36% and reached an all-time high of $58 per share yesterday, with a market cap valuation of $3.3bn. The biotech company is focused on developing targeted therapies for canc
